Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

MRNA-seq for etoposide-treated TLP-knockdown cells

ABSTRACT: mRNA-seq for etoposide-treated TLP-knockdown cells

PROVIDER: PRJNA494328 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR7948910.fastq.gz	Fastqsanger.gz
	SRR7948911.fastq.gz	Fastqsanger.gz
	SRR7948912.fastq.gz	Fastqsanger.gz
	SRR7948913.fastq.gz	Fastqsanger.gz
	SRR7948914.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

mRNA-seq for etoposide-treated TLP-knockdown cells

Project description:We explored the mechanism by which TLP affects DNA damage response. We performed mRNA-seq analysis of non-treated and etoposide-treated samples in control and TLP-knockdown cells. We show that TLP is critical for global transcriptional repression after double-strand DNA breaks (DSBs).

2018-10-03 | GSE120734 | GEO

RNA-seq data U2OS human osteosarcoma cell line etoposide treated with JMY knockdown

Project description:RNA-seq data U2OS human osteosarcoma cell line etoposide treated with JMY knockdown

| PRJEB55290 | ENA

Human colon cancer SW480 cells: stably transfected with vector control and LRP16 treated with or without etoposide

Project description:Transcriptional profiling of human colon cancer SW480 cells comparing control untreated SW480 cells with cells stably transfected with LRP16 treated with or without etoposide (50 μM) for the indicated periods (0,1hour, 3hours).An exploratory microarray analysis was performed with mRNA extracted from clutured SW480 cells transfected with LRP16 or control plasmid that were treated with or without etoposide. Total RNA of colon cancer cells stably transfected with vector control and LRP16 treated with or without etoposide (50 μM) for the indicated periods was isolated and purified using RNeasy Kit (Qiagen, Hilden, Germany). Integrity of RNA was assessed by using an Agilent BioAnalyser 2100 (Agilent Technologies).

2017-09-22 | GSE93625 | GEO

Supplementary Dataset 28 - HUNTER with etoposide-treated Jurkat cells

Project description:HUNTER analysis of N-terminal peptides from Jurkat cells treated with 50 uM etoposide for 8h

2023-06-21 | MSV000092232 | MassIVE

Supplementary Dataset 26 - CHOPPER with etoposide-treated Jurkat cells

Project description:CHOPPER (Chemical enrichment of protease sites with purchasable, elutable reagents, an N terminomics method) with etoposide-treated Jurkat cells

2023-02-11 | MSV000091272 | MassIVE

RNA seq_A375 gSMARCB1 + A549 etoposide, Aurora kinases inhibitors treated

Project description:To study the senescence gene signatures in the cells, which were genetic SMARCB1 depleted or treated with aurora kinase inhibitors or etoposide, we performed next generation RNA sequencing on these cell, and 'FRIDMAN_SENESCENCE_UP' geneset was used to determine the enrichment of senescence-related genes. The RNA sequencing results include (1) A375 cells and SMARCB1 depleted counterparts. (2) A549 cells and aurora kinase inhibitor (Alisertib, barasertib or tozasertib) or etoposide treated counterparts.

2017-09-21 | GSE102639 | GEO

RNA-seq data U2OS human osteosarcoma cell line etoposide treated with JMY knockdown

Project description:Effects of JMY on gene expression in U2OS under etoposide treatment

2023-04-20 | E-MTAB-12059 | biostudies-arrayexpress

Expression profiling of etoposide-induced senescent cells

Project description:We report here the RNA-seq data of proliferating IMR90 cells and etoposide-induced senescent cells with control or cGAS knockdown

2017-08-14 | GSE99028 | GEO

Expression profile of etoposide-resistant MCF7 (MCF7VP) cells with targeted RUNX2 knockdown

Project description:The second leading cause of cancer death for women in the U.S. is breast cancer, moreover, a significant number of patients with breast tumors acquire resistance to drugs during therapy. To develop targeted therapeutic strategies to combat drug resistance it is essential to understand the basic molecular mechanisms through which cancer cells control sensitivity to chemotherapeutics. To identify new candidate genes and facilitate the discovery of novel drug resistance pathways, we have generated a resistance profile or M-bM-^@M-^XresistomeM-bM-^@M-^Y of etoposide resitant MCF7 breast cancer cells. Differential expression of over 5000 genes (fold change > 2, P value < 0.05) indicate that several drug resistance mechanisms may be operating in these cells, including up-regulation of ABC transporter genes, down-regulation of the drug target and down-regulation of apoptotic genes. Several transcription factors such as RUNX2, SOX9, ETS1 and SMAD3 were up-regulated in the drug resistant cells. Targeted RUNX2 knockdown in the resistant cells using siRNA increased sensitivity to etoposide and also upregulated expression of pro-apoptotic genes indicating that RUNX2 could be a molecular target against etoposide resistance. Differential miRNA (microRNA) expression was observed among the drug resistant and sensitive cells suggesting that miRNA may also play a role in regulation of drug resistance. Hsa-miR-218, which targets ABCC6, was down-regulated in the drug resistant cell line. Transfection of a miR-218 mimic could down-regulate the expression of the efflux pump ABCC6 by 65% in drug resistant cells suggesting that regulation of miRNA may play an important role in etoposide resistance. RNA from etoposide-resistant MCF7 (MCF7VP) cell lines were hybridized to Affymetrix microarrays.

2011-04-08 | E-GEOD-28414 | biostudies-arrayexpress

Whole-genome CRISPR screen of etoposide-treated U2OS and U2OS p53KO cells, and RNAseq of U2OS cells incubated in media conditioned by etoposide-treated U2OS or U2OS p53KO cells.

Project description:CRISPR screen: U2OS or U2OS p53KO cells expressing Cas9 were transduced with a whole-genome library of CRISPR sgRNAs, then treated with either DMSO or etoposide. Differential sgRNA abundances were calculated for each condition and used to determine the effect of each single gene knockout on fitness and the drug-induced death rate. RNA-Seq: U2OS or U2OS p53KO cells were cultured with either DMSO or etoposide for 48 hours, and then U2OS cells were incubated in this conditioned media for 8 hours. RNA was collected and use to observe differential expression changes between conditions.

2023-05-17 | GSE232592 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data